11 while mineral bone disorders, including secondary hyperparathyroidism (HPT), were reported as more severe in uremic women than in men. [12][13][14] Sex-specific effects of vitamin D were also demonstrated in mice.
INTRODUCTION 25-hydroxy-vitamin D [25(OH)D]
is a widely accepted biomarker of the vitamin D status, also in end-stage renal disease (ESRD). 1 Patients with ESRD, including those on hemodialysis (HD), usually have low plasma vitamin D levels.
2,3
Vitamin D deficiency is epidemiologically linked to life-threatening diseases such as myocardial infarction (MI), 4-6 cerebral stroke, 5 and bone fractures, 7 the prevalence of which is related to sex. 4, [8] [9] [10] In dialysis patients, the above conditions are more frequent than in the general population. Male sex was shown to be associated with a higher frequency of Clinical and laboratory data Clinical data, obtained from 955 HD patients (565 men), included the prevalence of CAD and MI, frequency of PTX, and frequency of treatment with cinacalcet. CAD was diagnosed based on a medical history, electrocardiograms, exercise stress test, and, in some cases, on coronary angiography or computed tomography. MI was diagnosed based on a medical history and evidence showing characteristic electrocardiographic abnormalities and elevated levels of cardiac markers of cardiomyocyte damage.
Laboratory parameters included serum concentrations of total calcium, phosphorus, and PTH as well as serum activities of total alkaline DBP levels have been recently related to mortality in HD patients. 17 DBP is encoded by a group-specific component gene (GC) located on chromosome 4q13.3. In sparse data on the GC polymorphism in dialysis patients, median serum DBP concentrations were the lowest in HD patients with both rs7041 TT and rs4588 AA genotypes, 18 and the GC polymorphism was not associated with response to hepatitis B vaccination 19 or end-stage type 2 diabetic nephropathy. 20 Gene expression may be mediated by sex. Previous papers have reported a sex-specific association of vitamin D receptor (VDR) polymorphism combinations with type 1 diabetes 21 and growth during the first 2 years of life 22 in nonuremic subjects, but sex-dependent associations of GC and features of ESRD have not been investigated.
We evaluated the frequency distribution of GC polymorphisms in HD patients and healthy subjects and assessed differences in the prevalence of coronary artery disease (CAD), MI, and selected mineral metabolism disturbances of secondary HPT in HD patients with different GC polymorphic variants. To our knowledge, this is the first such analysis. Additionally, HD women and men were analyzed separately to explore possible sex-associated phenotype differences in relation to GC genotypes. Our findings may have a predictive value for establishing a genetic-related risk of developing ESRD-associated comorbidities and may help explain the differences in clinical and laboratory parameters between men and women on HD.
PATIENTS AND METHODS Patients and controls
A total of 1056 patients on HD (625 men) and 313 healthy controls (150 men) were enrolled into the study. All individuals were Caucasians and lived in the Wielkopolska region of Poland. Healthy individuals (unrelated blood donors and healthy volunteers) served as controls for the frequency distribution of GC polymorphic variants.
In HD patients, therapeutic efforts aimed to reach normal serum levels of calcium and phosphorus and to maintain serum intact parathyroid hormone (PTH) levels at a range of approximately 2 to 9 times the upper normal limit for the assay in accordance with the Kidney Disease: Improving Global Outcomes (KDIGO) Work Group clinical practice guidelines. 1 Patients with serum PTH levels exceeding 500 pg/ml received treatment with cinacalcet hydrochloride. 23 The number of patients using cinacalcet was limited by lack of reimbursement from the National Health Fund (Narodowy Fundusz Zdrowia). In HD patients with severe secondary HPT who failed to respond to pharmacological treatment (PTH levels exceeding 1000 pg/ml in repeated evaluations, suspicion of parathyroid gland adenoma on 99mTc-MIBI scintigraphy), parathyroidectomy (PTX) was performed if possible (no clinical contraindications, written informed consent obtained).
test for trend (P trend ). A power analysis was performed using the Fisher exact test.
The whole group of HD patients as well as HD women and HD men separately were divided according to their GC polymorphic variants for screening for phenotype-genotype associations. ORs with P values and 95% CIs were calculated using the contingency table for each tested phenotype separately, if it was a dichotomous variable. All probabilities were 2-tailed. For continuous variables, the Mann-Whitney test, t test, or Cochran-Cox test was used, as appropriate. Three models (dominant, recessive, and additive) of inheritance were applied for each GC polymorphism.
The P values with the Bonferroni correction for multiple testing were considered significant if a P value was lower than 0.017 (1 SNP, 3 models, 1 phenotype). Associations shown to be significant were tested together in selected groups of HD patients using the Bonferroni-corrected P values. In this case, a P value of 0.05 was divided by the product of the number of polymorphisms, number of basic models, and number of dependent variables of interest as described by Wypasek et al. 24 Associations that remained significant were analyzed using a logistic regression to show the magnitude of the genotype effect in relation to the 50th percentile of continuous variables. Covariates used for an adjustment were age and sex, where appropriate.
Multiple regression analysis was performed to determine whether genotypes shown as associated with specific phenotypes were also independent predictors of those phenotypes among other variables. The multivariable models included clinical characteristics of HD patients, laboratory parameters related to vitamin D and secondary HPT, and a GC polymorphic variant tested for associations. The number of variables included into the model depended on the size of the sample tested.
Statistical analysis was performed using GraphPad InStat 3.10, 32 bit for Windows, created July 9, 2009 (GraphPad Software, Inc., San Diego, California, United States), CytelStudio version 10.0, created January 16, 2013 (CytelStudio Software Corporation, Cambridge, Massachusetts, United States), and Statistica version 10, 2011 (Stat Soft, Inc., Tulsa, Oklahoma, United States).
A haplotype-based association analysis using a sliding window approach was performed using the Haploview 4.2 software. Statistical significance was assessed using the 1000-fold permutation test.
Ethical approval The research design was approved by the Institutional Review Board of the Poznan University of Medical Sciences, Poland. Informed consent was obtained from all study participants.
RESULTS
The main clinical and laboratory data of HD patients are presented in TABLE 1. Men showed a significantly higher prevalence of CAD phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and γ-glutamyltransferase (GGT). They were obtained from 827 HD patients (477 men). Each laboratory parameter was a mean value of 2 to 4 results obtained before the study enrollment depending on HD vintage. In patients who underwent PTX or were treated with cinacalcet, laboratory data obtained before those treatments were included in the analysis. It was not possible to obtain clinical and laboratory data from all patients in some private dialysis facilities because of their intrinsic regulations.
Additionally, plasma 25(OH)D levels were determined in 213 HD patients (120 men) blindly selected from the group of 827 patients who had all other laboratory data available. Blood samples for 25(OH)D were taken in the winter to avoid differences in sunlight exposure between patients who used to sunbathe and those who did not. Plasma 25(OH)D concentrations were measured in HD patients who had not been treated with vitamin D or had stopped such a treatment at least 3 weeks earlier.
Sex distribution was not significantly different between all HD patients (n = 1056), those who had all clinical data available (n = 955), those who had all laboratory data available (n = 827), and those tested for plasma 25(OH)D levels (n = 213).
Clinical and laboratory data were compared in HD patients with different polymorphic variants of the analyzed genotypes.
Laboratory methods To examine plasma 25(OH)D levels, a chemiluminescent microparticle immunoassay was used according to the manufacturer's instructions (Abbot Diagnostic ARCHITECT 25-OH VITAMIN D CMIA®, Mannheim, Germany). Other laboratory parameters were measured using standard laboratory assays.
Statistical methods
The results are presented as percentage for categorical variables, mean with 1 standard deviation for normally distributed continuous variables, or median (range) for nonnormally distributed continuous variables as tested by the Shapiro-Wilk test. A P value of less than 0.05 was considered significant.
The Hardy-Weinberg equilibrium (HWE) was tested to compare the observed genotype frequencies with the expected ones using the χ 2 test. Distributions of the tested polymorphisms were consistent with the HWE with the exception of GC rs1155563 in the entire HD group and in men. Repeated genotyping in all subjects with GC rs1155563 confirmed this lack of consistency (the rate of concordance between both analyses was 99.7%).
The Fisher exact probability test or the χ 2 test was used to evaluate the differences in genotype and allele prevalence between the groups. The odds ratios (ORs) with P values and 95% confidence intervals (CIs) were calculated. Polymorphisms were tested for associations using the χ
2
The results of screening for phenotype-genotype associations are presented in Supplementary material online, Tables S7-S15 . In all studied HD groups, no associations were revealed between GC polymorphic variants and clinical parameters (prevalence of CAD and MI; treatment with PTX or cinacalcet) and the majority of laboratory data (PTH and total calcium concentrations, total ALP activity). The only results suggesting an association with GC polymorphic variants were those for plasma 25(OH)D concentrations in the entire HD group and serum phosphorus levels in HD women.
HD patients showing the GC rs7041 TT genotype revealed significantly lower plasma 25(OH)D concentrations compared with those showing the GC rs7041 GG genotype (TABLE 3). HD individuals with the GC rs7041 TT genotype had an approximately 2-fold higher risk for plasma 25(OH)D levels below the 50the percentile (13.9 ng/ml) than HD subjects showing the GC rs7041 GG genotype (OR, 0.51; 95% CI, 0.29-0.88; sex-and age--adjusted P, 0.014). GC rs7041 GG or TT genotypes were used in the multiple regression analysis to investigate their predictive value among other variables in respect to 25(OH)D concentrations. The first model included the basic and MI, while women had lower serum 25(OH)D concentrations and higher serum calcium levels and ALP activity than men.
The analysis of HapMap CEU data showed that common (minor allele frequency, >0.2) GC SNPs resided in 2 distinct LD blocks (Supplementary material online, Figure S1 ). Within the LD blocks, the D' and r 2 values ranged from 0.73 to 1.00 and 0.42 to 1.00, respectively. The rs7041 and rs1155563 variants were in moderate pairwise LD with other SNPs within the first LD block (average r 2 = 0.77 and 0.61, respectively) and were good proxies (r 2 ≥0.8) for 4 of 12 common variants. The rs2298849 variant, located within the second LD block, was in perfect LD (r 2 = 1) with the intronic variant, rs1352845 (Supplementary material online, Figure S1 ).
Compared with healthy controls, HD patients did not differ in the frequency distribution of the tested GC polymorphic variants (TABLE 2). In addition, no differences were observed between the groups in relation to sex (Supplementary material online, Tables S3-5) .
The haplotype analysis of GC polymorphisms did not show any differences in haplotype frequencies between any of the study groups (Supplementary material online, Table S6 ). Abbreviations: ALP, total alkaline phosphatase; AST, alanine aminotransferase; GGT, γ-glutamyltransferase; HD, hemodialysis; PTH, parathyroid hormone; PTX, parathyroidectomy; RRT, renal replacement therapy GC rs7041 GG genotype was replaced by the GC rs7041 TT polymorphic variant (P value for the model, 0.0002). The GC rs7041 TT genotype was a significant negative predictor of 25(OH)D (β = -0.150; P = 0.04); other variables yielded similar significance as in the first model. However, lower plasma 25(OH)D concentrations in HD women compared with men occurred independently of the rs7041 polymorphic variant (P = 0.008 for the GG group; P = 0.002 for the GT group; P = 0.009 for the TT group; Mann-Whitney test).
When HD patients were divided according to sex, the only parameter possibly associated with the GC polymorphism was that of serum phosphorus levels in relation to GC rs7041 polymorphic variants in HD women. GC rs7041 TT women compared with GG ones showed higher serum characteristics of HD patients: age, renal replacement therapy (RRT) vintage, prevalence of the main causes of renal failure (diabetic nephropathy, hypertensive nephropathy, chronic glomerulonephritis, and chronic tubulointerstitial nephritis); CAD as associated with genetic variants related to the vitamin D pathway 25 ; laboratory parameters related to vitamin D and secondary HPT: calcium, phosphorus, PTH, total ALP as well as and GC rs7041 GG genotype (P value for the model, <0.0001). Significant positive predictors of 25(OH)D concentrations among RRT patients were serum calcium levels (β = 0.174; P = 0.002) and the GC rs7041 GG genotype (β = 0.247; P = 0.0005), whereas older age (β = -0.225; P = 0.004) and RRT vintage were negative predictors (β = -0.263; P = 0.001). In the second model, the a Mann-Whitney test, b nonsignificant after the Bonferroni correction (P >0.017), c significant after the Bonferroni correction (P <0.017)
For conversion factors to SI units, see In our study on patients with severely impaired renal function diagnosed as ESRD, there was no association of the examined GC polymorphisms and CAD/MI occurrence, independently of whether all HD patients were analyzed or men and women separately.
Several studies have shown that the GC polymorphism may contribute to the variation of serum 25(OH)D levels.
18,27-34 In a genome-wide association study, 3 SNPs in the GC (rs2282679, rs7041, and rs1155563) were identified as associated with 25(OH)D concentrations in the European population. The strongest association was observed for rs2282679, which is in moderate LD with rs7041. 32 According to genotype data from HapMap CEU samples, the r 2 and D' values for this pair of SNPs were 0.61 and 1.00, respectively. 32 In our study, lower 25(OH)D levels were shown in HD patients with the rs7041 TT genotype compared with carriers of the rs7041 GG polymorphic variant, and GC rs7041 was predictive for plasma 25(OH)D levels. Therefore, our results are in line with the earlier findings indicating that individuals who have 2 T alleles of the rs7041 missense variant are at risk for vitamin D deficiency. Additionally, we showed that the association of rs7041 with 25(OH)D was also evident in uremic milieu. A substitution of aspartic acid to glutamic acid at amino acid position 432 (Asp432Glu) of DBP attributed to the functional properties of the GC rs7041 variant located in exon 11 seems to be an important contributor to decreased plasma 25(OH)D levels, possible by inducing a lower affinity of 25(OH)D to DBP. HD women showed lower plasma 25(OH)D concentrations than men. However, the association of the rs7041 TT genotype with lower plasma 25(OH) D levels does not explain lower 25(OH)D levels phosphorus levels (Supplementary material online, Table S8 ). Women with the GC rs7041 TT genotype showed a 1.5-fold higher risk for serum phosphorus concentrations over the 50th percentile (5.07 mg/dl) than HD women with the GC rs7041 GG genotype (OR, 1.55; 95% CI, 1.05-2.31; ageadjusted P = 0.028). A significant association previously shown between the GC rs7041 polymorphism and plasma 25(OH)D concentrations in all HD patients (TABLE 3) was not observed either in men or women (Supplementary material online, Tables S8 and S11), probably owing to a lower power after dividing the whole tested group according to sex. Assuming that this significance could be observed in larger samples of both sexes, 2 phenotypes together [25(OH)D and phosphorus] were also tested in women for association with GC rs7041. Addition of another phenotype did not abolish the significance of an association between GC rs7041 and serum phosphorus levels, although the Bonferroni-corrected P value required to confirm significance had to be lower (TABLE 4) .
Diabetic nephropathy (β, 0.208; P = 0.03), serum PTH levels (β, 0.229; P = 0.02), and the GC rs7041 TT genotype (β, 0.197; P = 0.04) were positive predictors, while age was a negative predictor (β, -0.259; P = 0.01) of serum phosphorus levels in HD women. Other predictors used in this model (P <0.0005) included RRT vintage, hypertensive nephropathy, 25(OH)D, and calcium. The number of variables used in this model was smaller because the group was divided into subgroups according to sex, which reduced the number of subjects available for the regression analysis.
An association was also suspected between 25(OH)D and rs1155563, but the level of significance was not achieved (Supplementary Tables  12 and 15) . DISCUSSION Dialysis patients are at a higher risk of CAD and MI compared with healthy individuals.
26 Associations of genetic variants Data are presented as median (range).
a Mann -Whitney test, b nonsignificant after the Bonferroni correction (P >0.008), c significant after the Bonferroni correction (P <0.008)
For conversion factors to SI units, see TABLE 1 Abbreviations: see TABLE 2 HD patients, hyperphosphatemia contributes directly to an increase in PTH levels despite normal or high serum calcium concentrations. 36 The question remains what might be the possible link between GC rs7041 polymorphic variants and serum phosphorus concentrations only in women. In ESRD patients, vitamin D deficiency is frequently seen concomitantly with hyperphosphatemia. Although the causes of hyperphosphatemia in ESRD are multifactorial, it cannot be excluded that both low vitamin D levels and skeletal resistance to PTH action shown in uremic milieu (partially due to low vitamin D) 37 may contribute to increased phosphorus levels. The development of PTH resistance is related to female sex. 38 However, there is no clear explanation how the phenotypes related to vitamin D itself or vitamin D pathway genes are mediated by sex. Studies showing sex-specific association of VDR polymorphisms with type 1 diabetes 21 or growth during the first 2 years of life 22 did not provide any explanation. Experimental studies in mice suggest that there is synergy between ovarian hormones and vitamin D. 15 We might postulate that higher phosphorus levels in HD women with the GC rs7041 TT genotype, but not men, may be related to the effects of ovarian hormones on the expression of this specific GC polymorphic variant.
Our study has several limitations. First, the study groups were relatively small, especially when divided into subgroups according to sex. It made it difficult to obtain statistical significance in comparisons that included the data on minor allele homozygosity, and when the Bonferroni correction for multiple comparison was used. On the other hand, the Bonferroni correction 39 has been criticized, and not all authors use it in genetic studies, especially when the established associations are investigated in more detail or in a more uniform cohort. 40, 41 The GC rs7041 TT genotype has already been associated with lower plasma 25(OH) concentrations, 27-33 but in HD subjects, only in combination with the rs4588 AA genotype.
18 The HD group in our study was heterogeneous with regards to the causes of ESRD. However, the development of ESRD substantially reduces clinical variability between patients related to underlying kidney damage and exposes the signs and symptoms related to uremic toxicity. Our recent study has shown that patients with end-stage type 2 diabetic nephropathy did not differ in the frequency distribution of GC polymorphic variants from controls, patients with other causes of ESRD as a whole, as well as subjects with chronic glomerulonephritis, chronic infective tubulointerstitial nephritis, and hypertensive nephritis, showing glomerular filtration category 5 and requiring RRT.
20 However, differences in this respect between other specific causes of ESRD have not been excluded so far. Second, the number of selected polymorphisms in our study was insufficient to fully cover the GC gene. The analyzed variants were not good or perfect proxies (r 2 ≥0.8 or 1.00, respectively) for all other in HD women compared with men because women showed lower 25(OH)D levels at all 3 rs7041 genotypes.
Similarly to GC rs7041, also GC rs1155563 is known to be associated with plasma 25(OH)D levels. 32 In HD subjects, specifically in men, this association had borderline significance. However, in all HD patients, and separately in men, the distribution of polymorphic variants of GC rs1155563 was not consistent with the HWE. In our previous study, the nonconsistency of GC rs1155563 polymorphic variants with the HWE was shown in nonresponders to hepatitis B vaccination, although genotyping was also repeated. 19 It is not clear why HD subjects show deviations in this polymorphism.
Mineral bone disorders, including secondary HPT, are reported to be more severe in dialysis women than in men. 12,13 Serum intact PTH concentrations do not always allow to assess the presence or severity of secondary HPT. 1 In our study, serum PTH levels were similar in women to those in men even though PTH levels before PTX or cinacalcet treatment were included in the analysis. On the other hand, PTX and cinacalcet were used for secondary HPT treatment more often in women compared with men (however, statistical significance was borderline). Repeated measurements of total ALP activity are recommended for HD patients without clinically evident liver disorders to determine the bone turnover status as indicative of secondary HPT severity. 1 Considering the possibility of an increasing contribution of the liver-derived isoenzyme of ALP to its total activity in the case of increased activities of other liver enzymes, we additionally analyzed the serum activity of total ALP with the exclusion of patients with ALT, AST, and GGT activities exceeding 45 U/l. This analysis confirmed a higher total ALP activity in women than in men, which suggests a higher bone turnover related to secondary HPT in the female group. In patients undergoing PTX due to secondary HPT, women had lower preoperative bone mineral density than men, although no differences in the preoperative calcium-phosphorus product, ALP, or PTH were observed.
12 Significantly higher calcium concentrations in HD women could reduce differences in serum PTH levels compared with HD men, although serum ALP activities indicated more severe secondary HPT in women. We did not observe any associations between the GC polymorphisms and PTH levels or ALP activity. However, HD women with the rs7041 TT genotype showed higher serum phosphorus levels compared with those positive for the rs7041 GG genotype. No similar observation was made in HD men. It indicates that minor allele T rs7041 homozygosity in HD women is associated with abnormalities promoting secondary HPT, namely, hyperphosphatemia and low plasma levels of 25(OH) D. Hyperphosphatemia appears to be particularly important because high phosphorus concentrations can directly stimulate PTH synthesis. common
In summary, HD patients do not differ in the distribution of GC polymorphisms rs2298849, rs7041, and rs1155563 from healthy subjects. HD patients show an association between the GC rs7041 polymorphism and plasma 25(OH)D levels. Sex-related factors may be important for studying associations between GC rs7041 polymorphic variants and serum phosphorus concentrations. The clinical relevance of these findings, especially the association between the GC rs7041 polymorphism and sex-related severity of secondary HPT, requires further research.
Supplementary material online Supplementary material online is available with the online version of the article at www.pamw.pl.
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WNIOSKI Pacjenci leczeni hemodializami nie różnią się pod względem dystrybucji polimorfizmów GC (rs2298849, rs7041 oraz rs1155563) od osób zdrowych. U chorych HD występuje powiązanie między polimorfizmem GC i stężeniem 25(OH)D w osoczu. Czynniki zależne od płci mogą być ważne w ekspresji powiązań między wariantami polimorficznymi GC a zaburzeniami mineralnymi. TABLE 7 Abbreviations: see TABLES 3 and 7 
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